Moderna Cancer Vaccine Data Confirms 42% Recurrence Cut
Moderna cancer vaccine data confirms a 42% cut in melanoma recurrence risk, but an ESMO embargo breach triggered wild swings in MRNA shares.
Topic
Oncology
Every Financial News story tagged Oncology, newest first.
- Stories
- 8
- Last updated
- Follow
- RSS feed
Moderna stock plunges 25% after melanoma vaccine data leak
A melanoma vaccine data leak wiped $24bn off Moderna before its Madrid presentation, despite a statistically strong Phase 3 result.
Cencora to buy American Oncology Network in $2.4bn deal
Cencora agrees to buy American Oncology Network for $2.4bn enterprise value, but a stockholder rollover means it may land only 75% of…
More in Oncology
1–8 of 8
Adlai Nortye lines up Lilly, Merck KGaA for AN4035 trial
Adlai Nortye clinical collaboration with Lilly and Merck KGaA will test AN4035 plus cetuximab, as ANL shares trade 26% below their 20-day high.
AstraZeneca invests $2bn in Summit Therapeutics for cancer drug deal
AstraZeneca's $2bn Summit Therapeutics investment pairs preferred equity with a cancer drug trial tie-up, sending Summit shares sharply higher.
McKesson to buy Precision Medicine Group for ~$2.25bn
McKesson's Precision Medicine Group acquisition, worth ~$2.25bn, deepens its push into oncology and specialty services, filings show.
PhoreMost Advances Cancer Treatment with $50M Funding Boost
PhoreMost, a biopharmaceutical leader, has secured an additional $12 million in Series B financing, raising its total to over $50 million.This funding boost, led by Parkwalk Advisors, supports its mission…
Valar Labs Secures $22M to Transform AI-Driven Cancer Diagnostics
Valar Labs, a leader in AI-based medical diagnostics, has secured $22 million in Series A funding. This milestone will advance their groundbreaking technologies in cancer diagnosis.The funding round, co-led by…
